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ing, p=O.O07, role limitation due to physical problems, p=O.O47, role limitation due to 
emotional problems, p&036, and vitality, p=O.OOO). but not the type of randomized strat- 
egy. Also patients < 69 years (social functioning, ~~0.03, and pain, p=O.O44), AF duration 
< 1 month (social functioning, p=O.O32), and those with complaints of AF at baseline (role 
limitation due to physical problems, p=O.O41) showed QoL Improvement. 
Conclusion: Maintenance of sinus rhythm rather than the assigned strategy is ah impor- 
tant parameter for improvement of QoL. 
benefit of maintaining SR beyond preventing symptoms. 
9:45 a.m. 
Objective: To test retrospectively the hypothesis that long-term maintenance of SR 
translates in prolonged survival and reduced morbidity. 
Methods: 569 ablated patients (pts) (mean age, 65 * 9 yrs; chronic AF, 21%; mean AF 
duration. 2.9 yrs) were compared with 562 (65 * 10 yrs; chronic AF. 19%; mean AF dura- 
tion, 2.1 yrs) who were given antiarrhythmic drugs for preventing recurrent AF, between 
January 1996 and March 2001. For both groups follow-up, including serial visits, 24-hour 
Halter recordings and echocardiograms, began at hospital discharge, ended in March 
2002, and averaged 664 days. 
Results: At final analysis, 20% of ablated patients and 56% among medically treated 
have had their first relapses (P<O.OOi, by log-rank statistic). Cox proportional hazard 
model revealed ablation was J-fold as efficacious as drugs in preventing recurrences 
(hazard ratio [HR], 0.31, 95%CI 0.22 to 0.47, P=O.O02). When entered as a timedepen- 
dent variable into the Cox model, maintenance of SR, was associated with substantial 
reductions in the risk of death (HR, 0.46, 95%CI 0.22 to 0.66: P<O.OOl) and major mor- 
bidities mainly due to heart failure and stroke (HR, 0.45, 95%CI 0.21 to 0.57; P<O.OOl), 
either considering all patients or the two treatment groups separately (ratio of HRs 0.99, 
PzO.76). 
Conclusion: These results question the conclusions of the AFFIRM trial about the lack 
of benefit of SR control over rate control by drugs in AF pts, and substantiate the claim 
that obtaining SR is more important than using SR as a marker of good health. That SR 
resulted as a strong prognostic deteninant reinforces the concept that, AF, by itself or 
as hastening factor, may cause excess modality and morbidity. Thereby, its prevention 
and suppression should always be pursued. 
803-3 The Detection of Left Atrial Thrombi in Patients With 
Atrial Fibrillation Were Associated With 
Thromboembolic Events During Long-Term Follow-Up 
Karlheinz Seidl, Margit Vater, Monika Rameken, Andreas Brandt, Axel Droegafhueller, 
Jochen Senges, Head Center, Ludwigshafen. Germany 
Aim of the study was evaluate the long-term outcome in patients (pts) with atrial fibrilla- 
tion (AF), in whom a left atrial thrombus was detected by transesophageal echocardio- 
graphy (TEE) in comparison to pts without thrombus. 
Methods: In this single center observational study all pts were enrolled in this analysis if 
they were admitted to our hospital for the first time with the attention to cardioved atrial 
fibrillation in sinus rhythm. 
Results: Overall 447 pts were included in this study and in all pts TEE was performed. In 
42 pts the left atrial thrombus was detected. 34 of these 42 pts (60%) were effectively 
anticoagulated with ah INR (2 - 3). TEE was repeated in 31 of these 42 pts after 4 - 6 
weeks. No left atrial thrombus was found in 20 pts. These 20 pts were then cardioverted. 
In the remaining 11 pts the left atrial thrombus was still present. During follow up of a 
median of 20 months 4 of these 42 pts had ah embolic event (9.5%). All pts with a throm- 
bus had ah effective anticoagulation (INR 2-3) after discharge of the hospital. During the 
same follow up period 12/405 pts without a thrombus had a thromboembolic event 
(2.6%). Of these 405 pts 63% were effectively anticoagulated. Conclusion: Embolic event 
rate in pts with a left atrial thrombus is 9.5% in contrast to only 2.6% in pts without a 
thrombus during a median follow-up time of 20 months. 
lo:oo a.m. 
803-4 An Endovascular Approach to Stroke Prevention in 
Atrial Fibrillation: Results of the Multicenter PLAATO 
(Percutaneous Left Atrial Appendage Transcatheter 
Occlusion) Feasibility Trial 
Mark Reisman, William Gray, Horst Sievert. Paul Kramer, Peter C. Block, Carlo DiMario, 
Antonio L. Badorelli, Paolo Della Bella, Heyder Omran. Athena Poppas, David 0. 
Williams, Allan Skanes, Bernhard Meier, Toshiko Nakai, Michael D. Lesh, Swedish Head 
Institute, Seattle, WA 
Bsckground: Thromboembotism due to atrial fibrillation (AF) is a frequent cause of 
stroke. During non-rheumatic AF, thrombus originates predominantly in the left atrial 
appendage &AA). Anticoagulation (warfarin) therapy has demonstrated a two-thirds 
reduction in stroke risk. In pts suboptimal for wadarin therapy, occlusion of the LAA may 
significantly reduce the risk of thromboembolism. The purpose of this phase one study is 
to determine the safety and feasibility of the PLAATOTM procedure in high risk AF pts 
who are poor warfarin candidates. 
Methods: Patients were enrolled who have chronic or paroxysmal AF and are at high 
risk for stroke based oh the presence of congestive heart failure, diabetes mellitus, 
hypertension, history of Stroke/transient ischemic attack (TIA), or high-risk echo findings 
with transesophageal echocardiography (TEE). Patients with existing LAA thrombus 
ware excluded. The PLAATO system consists of a self-expanding cage covered with 
ePTFE delivered through a 12Fr transseptal sheath specially designed to access the 
LAA. Device placement is guided by fluoroscopy and TEE. 
Results: A total of 56 pts, age 7Oi7 yrs (M/F=36/20) were enrolled. Device deployment 
was successful in 55156 pts (96%). One pt had a groin complication during venous 
access so the procedure was aboded. Seventeen of 56 pts had a history of Stroke/IA 
and 26156 pts had high risk echo findings defined as low LAA emptying velocity or spon- 
taneous echo contrast in the LAA. Devices were oversized by 20%.50% of LAA diame- 
ter. Procedure time was 76*30 min. Procedural complication occurred in 6 pts (10%) and 
included 3 pedcardial effusion, 2 groin hematoma and 1 false aneurysm. Clinical follow- 
up at 6 mos (33 pts) included 1 death (not device related) and 0 CVA’s. TEE follow-up at 
6 mos (16 pts) confirmed stable implant position with a smooth atrial-facing SurfaCe. In 
one pt, a smooth echodense layer was seen along device surface at 1 and 6 mos, which 
resolved at 9 mos: ho clinical events have occurred in this pt. 
Conclusions: Transcatheter occlusion of the LAA with a novel implantable device 
appears feasible and safe. Whether or not it confers protection against stroke will be 
predicated from our long term clinical follow-up. 
10:15 a.m. 
803-5 Sinus Rhythm Control in Atrial Fibrillation: Outcomes 
From a Controlled Long-Term Ablation Study 
Carlo Pawone, Salvatore Rosanio, Giuseppe Augello, Alessia Pappone, Patrizio 
Mazzone, Simone Gullena, Mario Pittalis, Gabriele Pagfino, Gabriele Vicedomini. San 
Raffaele University Hospital, Milan, Italy 
Background: Atrial fibrillation (AF) is associated with a 1.5- to 1.9-fold modality risk and 
2.6-to 4.5-fold risk of stroke as compared with subjects in sinus rhythm (SR). Circumfer- 
ential pulmonary vein ablation (CPVA) has emerged as safe and effective treatment for 
curing atrial fibrillation (AF). However only limited evidence exists to support a clinical 
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814-l Lack of OT Prolongation With Amiodarone Increases 
Arrhythmic Risk 
Peter Smetana, Esther Pueyo, Katerina Hnatkova. Marek Malik, St. George’s Hospital 
Medical School, London, United Kingdom 
Background:The superior anti-arrhythmic efficacy of amiodarone (A) is padly explained 
by ah almost heart rate independent prolongation of the QT inteival. Thus A treated 
patients with reduced QT prolongation might be at higher arrhythmic risk. We therefore 
investigated QT intervals at different heart rates in A and placebo (P) treated post-myo- 
cardial infarction (Ml) patients. Methods: In 24-hours recordings from 666 EMIAT 
patients (462 A, 404 P) obtained 1 month after randomisation, QT intervals were 
obtained automatically by using the Pathfinder software (Reynolds Med Tee). QT values 
were averaged over 10.ms RR interval bins from 550 to 1150 ms in each recording. 
Results were compared between survivors (SUR, circles) and victims of non-arrhythmic 
(NAD. dots) and arrhythmic death (AD, triangles) both in A (left panel) and P (right panel) 
groups. Results: As expected QT intervals were significantly longer at all investigated 
RR interval bins oh A. However, whereas there was ho significant difference in the QT 
intervals between SUR, NAD and AD patients in the P arm (SUR vs AD at 540-550 ms: 
336+ 25 vs 337i 23 ms, p=ns and at 1140-l 150 ms: 426+ 40 vs 417~ 46 ms, p=ns), QT 
intervals in the A arm were shorter in AD patients than in SUR at all RR interval bins 
(SUR vs AD at 540-550 ms: 349+ 24 vs 346+ 20 tns, p=ns and at 1140-l 150 ms: 469i 
40 “s 423+ 20 ms, p=2x 1 Od) 
Conclusions: Reduced prolongation of QT interval by A increases the risk of AD in post- 
Ml patients. 
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